The physiological roles of primary phospholipase C

Advances in Biological Regulation

Volumn 53, Issue 3, 2013, Pages 232-241

  Yang, Yong Ryoul ^a   Follo, Matilde Y ^b   Cocco, Lucio ^b   Suh, Pann Ghill ^a  

^a Ulsan National Institute of Science and Technology   (South Korea)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; PHOSPHOLIPASE C;

ANIMAL; DISEASES; GENETICS; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE; HUMANS; ISOENZYMES; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES;

EID: 84885769048     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.08.003     Document Type: Review

References (92)

1. Arteaga C.L., Johnson M.D., Todderud G., Coffey R.J., Carpenter G., Page D.L. Elevated content of the tyrosine kinase substrate phospholipase c-gamma-1 in primary human breast carcinomas. P Natl Acad Sci USA 1991, 88:10435-10439.
2. Bertagnolo V., Benedusi M., Brugnoli F., Lanuti P., Marchisio M., Querzoli P., et al. Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis 2007, 28:1638-1645.
3. Bertagnolo V., Benedusi M., Querzoli P., Pedriali M., Magri E., Brugnoli F., et al. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. Int J Oncol 2006, 28:863-872.
4. Bornfeldt K.E., Raines E.W., Nakano T., Graves L.M., Krebs E.G., Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994, 93:1266-1274.
5. Chen P., Xie H., Sekar M.C., Gupta K., Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994, 127:847-857.
6. Choi W.C., Gerfen C.R., Suh P.G., Rhee S.G. Immunohistochemical localization of a brain isozyme of phospholipase C (PLC III) in astroglia in rat brain. Brain Res 1989, 499:193-197.
7. Derman M.P., Chen J.Y., Spokes K.C., Songyang Z., Cantley L.G. An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem 1996, 271:4251-4255.
8. di Giacomo V., Matteucci A., Stellacci E., Battistini A., Di Baldassarre A., Capitani S., et al. Expression of signal transduction proteins during the differentiation of primary human erythroblasts. J Cell Physiol 2005, 202:831-838.
9. Ebinu J.O., Stang S.L., Teixeira C., Bottorff D.A., Hooton J., Blumberg P.M., et al. RasGRP links T-cell receptor signaling to Ras. Blood 2000, 95:3199-3203.
10. Faenza I., Bavelloni A., Fiume R., Lattanzi G., Maraldi N.M., Gilmour R.S., et al. Up-regulation of nuclear PLCbeta1 in myogenic differentiation. J Cell Physiol 2003, 195:446-452.
11. Faenza I., Bavelloni A., Fiume R., Santi P., Martelli A.M., Maria Billi A., et al. Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. J Cell Physiol 2004, 200:291-296.
12. Faenza I., Billi A.M., Follo M.Y., Fiume R., Martelli A.M., Cocco L., et al. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res 2005, 25:2039-2041.
13. Faenza I., Blalock W., Bavelloni A., Schoser B., Fiume R., Pacella S., et al. A role for PLCbeta1 in myotonic dystrophies type 1 and 2. Faseb J 2012, 26:3042-3048.
14. Faenza I., Matteucci A., Bavelloni A., Marmiroli S., Martelli A.M., Gilmour R.S., et al. Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in friend erythroleukemia cells. Biochim biophys acta 2002, 1589:305-310.
15. Falasca M., Sala G., Dituri F., Raimondi C., Previdi S., Maffucci T., et al. Phospholipase C gamma 1 is required for metastasis development and progression. Cancer Res 2008, 68:10187-10196.
16. Ferrer I., Goutan E., Marin C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000, 866:257-261.
17. Fili C., Malagola M., Follo M.Y., Finelli C., Iacobucci I., Martinelli G., et al. Prospective phase II study on 5-days azacitidine for treatment of Symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res 2013, 19:3297-3308.
18. Fiume R., Faenza I., Matteucci A., Astolfi A., Vitale M., Martelli A.M., et al. Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. J Biol Chem 2005, 280:24221-24226.
19. Fiume R., Ramazzotti G., Teti G., Chiarini F., Faenza I., Mazzotti G., et al. Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. Faseb J 2009, 23:957-966.
20. Follo M.Y., Faenza I., Fiume R., Ramazzotti G., McCubrey J.A., Martelli A.M., et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul 2012, 52:2-6.
21. Follo M.Y., Finelli C., Bosi C., Martinelli G., Mongiorgi S., Baccarani M., et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008, 22:198-200.
22. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Bosi C., Testoni N., et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009, 106:16811-16816.
23. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Chiarini F., Ramazzotti G., et al. Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011, 25:271-280.
24. Follo M.Y., Marmiroli S., Faenza I., Fiume R., Ramazzotti G., Martelli A.M., et al. Nuclear phospholipase C beta1 signaling, epigenetics and treatments in MDS. Adv Biol Regul 2013, 53:2-7.
25. Follo M.Y., Mongiorgi S., Clissa C., Paolini S., Martinelli G., Martelli A.M., et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia 2012, 26:2474-2482.
26. Follo M.Y., Mongiorgi S., Finelli C., Clissa C., Ramazzotti G., Fiume R., et al. Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem 2010, 109:1065-1071.
27. Follo M.Y., Mongiorgi S., Finelli C., Piazzi M., Faenza I., Ramazzotti G., et al. Nuclear PI-PLCbeta1 and myelodysplastic syndromes: genetics and epigenetics. Curr Pharm Des 2012, 18:1751-1754.
28. Follo M.Y., Russo D., Finelli C., Mongiorgi S., Clissa C., Fili C., et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012, 26:943-950.
29. Gines S., Bosch M., Marco S., Gavalda N., Diaz-Hernandez M., Lucas J.J., et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 2006, 23:649-658.
30. Giralt A., Rodrigo T., Martin E.D., Gonzalez J.R., Mila M., Cena V., et al. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 2009, 158:1234-1250.
31. Hannan A.J., Kind P.C., Blakemore C. Phospholipase C-beta1 expression correlates with neuronal differentiation and synaptic plasticity in rat somatosensory cortex. Neuropharmacology 1998, 37:593-605.
32. Hashimoto A., Takeda K., Inaba M., Sekimata M., Kaisho T., Ikehara S., et al. Cutting edge: essential role of phospholipase C-gamma 2 in B cell development and function. J Immunol 2000, 165:1738-1742.
33. He X.P., Pan E., Sciarretta C., Minichiello L., McNamara J.O. Disruption of TrkB-mediated phospholipase Cgamma signaling inhibits limbic epileptogenesis. J Neurosci 2010, 30:6188-6196.
34. Hokin M.R., Hokin L.E. Enzyme secretion and the incorporation of P32 into phospholipides of pancreas slices. J Biol Chem 1953, 203:967-977.
35. Homma Y., Takenawa T., Emori Y., Sorimachi H., Suzuki K. Tissue- and cell type-specific expression of mRNAs for four types of inositol phospholipid-specific phospholipase C. Biochem Biophys Res Commun 1989, 164:406-412.
36. Ihle J.N., Wang D.M., Feng J., Wen R.R., Marine J.C., Sangster M.Y., et al. Phospholipase C gamma 2 is essential in the functions of B cell and several Fc receptors. Immunity 2000, 13:25-35.
37. Jang H.J., Yang Y.R., Kim J.K., Choi J.H., Seo Y.K., Lee Y.H., et al. Phospholipase C-gamma1 involved in brain disorders. Adv Biol Regul 2013, 53:51-62.
38. Kim D., Jun K.S., Lee S.B., Kang N.G., Min D.S., Kim Y.H., et al. Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 1997, 389:290-293.
39. 2+ signaling. Cell Signal 2011, 23:1022-1029.
40. Kim Y.H., Park T.J., Lee Y.H., Baek K.J., Suh P.G., Ryu S.H., et al. Phospholipase C-delta 1 is activated by capacitative calcium entry that follows phospholipase C-beta activation upon Bradykinin stimulation. J Biol Chem 1999, 274:26127-26134.
41. Kundra V., Escobedo J.A., Kazlauskas A., Kim H.K., Rhee S.G., Williams L.T., et al. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature 1994, 367:474-476.
42. Kurian M.A., Meyer E., Vassallo G., Morgan N.V., Prakash N., Pasha S., et al. Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. Brain 2010, 133:2964-2970.
43. Kurosaki T., Maeda A., Ishiai M., Hashimoto A., Inabe K., Takata M. Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev 2000, 176:19-29.
44. Kurosaki T., Okada T. Regulation of phospholipase C-gamma2 and phosphoinositide 3-kinase pathways by adaptor proteins in B lymphocytes. Int Rev Immunol 2001, 20:697-711.
45. Lassar A.B., Skapek S.X., Novitch B. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 1994, 6:788-794.
46. Li S., Wang Q., Wang Y., Chen X., Wang Z. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration. Mol Endocrinol 2009, 23:901-913.
47. Lidonnici M.R., Corradini F., Waldron T., Bender T.P., Calabretta B. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood 2008, 111:4771-4779.
48. Lin X., Wang D. The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin Immunol 2004, 16:429-435.
49. Lo Vasco V.R., Cardinale G., Polonia P. Deletion of PLCB1 gene in schizophrenia-affected patients. J Cell Mol Med 2012, 16:844-851.
50. Lo Vasco V.R., Longo L., Polonia P. Phosphoinositide-specific Phospholipase C beta1 gene deletion in bipolar disorder affected patient. J Cell Commun Signal 2013, 7:25-29.
51. Martelli A.M., Billi A.M., Gilmour R.S., Neri L.M., Manzoli L., Ognibene A., et al. Phosphoinositide signaling in nuclei of Friend cells: phospholipase C beta down-regulation is related to cell differentiation. Cancer Res 1994, 54:2536-2540.
52. Martelli A.M., Evangelisti C., Follo M.Y., Ramazzotti G., Fini M., Giardino R., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in cancer stem cells. Curr Med Chem 2011.
53. Martelli A.M., Fiume R., Faenza I., Tabellini G., Evangelista C., Bortul R., et al. Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction. Histology and Histopathology 2005, 20:1251-1260.
54. Martelli A.M., Tabellini G., Ricci F., Evangelisti C., Chiarini F., Bortul R., et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Adv Biol Regul 2012, 52:214-227.
55. Martin T.A., Davies G., Ye L., Lewis-Russell J.A., Mason M.D., Jiang W.G. Phospholipase-C gamma-1 (PLC gamma-1) is critical in hepatocyte growth factor induced invitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol-semin Ori 2008, 26:386-391.
56. Matteucci A., Faenza I., Gilmour R.S., Manzoli L., Billi A.M., Peruzzi D., et al. Nuclear but not cytoplasmic phospholipase C beta 1 inhibits differentiation of erythroleukemia cells. Cancer Res 1998, 58:5057-5060.
57. Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 2009, 10:850-860.
58. Minichiello L., Calella A.M., Medina D.L., Bonhoeffer T., Klein R., Korte M. Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 2002, 36:121-137.
59. Missiroli S., Etro D., Buontempo F., Ye K., Capitani S., Neri L.M. Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int J Biochem Cell Biol 2009, 41:570-577.
60. Mongiorgi S., Follo M.Y., Clissa C., Giardino R., Fini M., Manzoli L., et al. Nuclear PI-PLC beta1 and Myelodysplastic syndromes: from bench to clinics. Curr Top Microbiol Immunol 2012, 362:235-245.
61. Morris J.F., Rauscher F.J., Davis B., Klemsz M., Xu D., Tenen D., et al. The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter invitro. Blood 1995, 86:3640-3647.
62. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
63. Noh D.Y., Lee Y.H., Kim S.S., Kim Y.I., Ryu S.H., Suh P.G., et al. Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues. Cancer 1994, 73:36-41.
64. O'Carroll S.J., Mitchell M.D., Faenza I., Cocco L., Gilmour R.S. Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. Cell Signal 2009, 21:926-935.
65. 2+ influx in Purkinje cells. Neuron 2001, 32:113-122.
66. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013, 14:7-23.
67. Peruzzi D., Aluigi M., Manzoli L., Billi A.M., Di Giorgio F.P., Morleo M., et al. Molecular characterization of the human PLC beta1 gene. Biochim biophys acta 2002, 1584:46-54.
68. Piccolo E., Innominato P.F., Mariggio M.A., Maffucci T., Iacobelli S., Falasca M. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 2002, 21:6520-6529.
69. Ramazzotti G., Faenza I., Fiume R., Matteucci A., Piazzi M., Follo M.Y., et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol 2011, 226:14-20.
70. Ramazzotti G., Faenza I., Gaboardi G.C., Piazzi M., Bavelloni A., Fiume R., et al. Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. Cell Signal 2008, 20:2013-2021.
71. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747.
72. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001, 70:281-312.
73. Ross C.A., MacCumber M.W., Glatt C.E., Snyder S.H. Brain phospholipase C isozymes: differential mRNA localizations by in situ hybridization. Proc Natl Acad Sci U S A 1989, 86:2923-2927.
74. Samelson L.E., Sommers C.L., Lee J., Steiner K.L., Gurson J.M., DePersis C.L., et al. Mutation of the phospholipase C-gamma 1-binding site of LAT affects both positive and negative thymocyte selection. J Exp Med 2005, 201:1125-1134.
75. Shepard C.R., Kassis J., Whaley D.L., Kim H.G., Wells A. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 2007, 26:3020-3026.
76. Shien T., Doihara H., Hara H., Takahashi H., Yoshitomi S., Taira N., et al. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). Breast Cancer 2004, 11:367-373.
77. Smrcka A.V., Brown J.H., Holz G.G. Role of phospholipase Cepsilon in physiological phosphoinositide signaling networks. Cell Signal 2012, 24:1333-1343.
78. Sommers C.L. A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 2002, 296:2040. 298:364.
79. Spires T.L., Molnar Z., Kind P.C., Cordery P.M., Upton A.L., Blakemore C., et al. Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb Cortex 2005, 15:385-393.
80. 2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 1983, 306:67-69.
81. Takenawa T., Homma Y., Emori Y. Properties of phospholipase C isozymes. Methods Enzymol 1991, 197:511-518.
82. Thore S., Dyachok O., Gylfe E., Tengholm A. Feedback activation of phospholipase C via intracellular mobilization and store-operated influx of Ca2+ in insulin-secreting beta-cells. J Cell Sci 2005, 118:4463-4471.
83. 2+ influx in insulin-secreting cells. J Biol Chem 2004, 279:19396-19400.
84. Wallace M.A., Claro E. A novel role for dopamine: inhibition of muscarinic cholinergic-stimulated phosphoinositide hydrolysis in rat brain cortical membranes. Neurosci Lett 1990, 110:155-161.
85. Wange R.L. LAT, the linker for activation of T cells: a bridge between T cell-specific and general signaling pathways. Sci STKE 2000, re1.
86. Wen R.R., Fu G.P., Chen Y.H., Yu M., Podd A., Schuman J., et al. Phospholipase C gamma 1 is essential for T cell development, activation, and tolerance. J Exp Med 2010, 207:309-318.
87. Xiao W., Hong H., Kawakami Y., Kato Y., Wu D., Yasudo H., et al. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009, 16:161-171.
88. Xie Z., Peng J., Pennypacker S.D., Chen Y. Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration. Biochem Biophys Res Commun 2010, 399:425-428.
89. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.P., Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem 2006, 281:12941-12949.
90. Young K.W., Nash M.S., Challiss R.A., Nahorski S.R. Role of Ca2+ feedback on single cell inositol 1,4,5-trisphosphate oscillations mediated by G-protein-coupled receptors. J Biol Chem 2003, 278:20753-20760.
91. Zhou Q., Lee G.S., Brady J., Datta S., Katan M., Sheikh A., et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012, 91:713-720.
92. Zuccato C., Marullo M., Conforti P., MacDonald M.E., Tartari M., Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 2008, 18:225-238.